Drug Discovery, Drug Research Editorial

1. Nothing To See Here! Just Big Pharma Investments In China 4/22/2024

   WuXi AppTec assists U.S.-based biotechs to develop and supply drugs to U.S. patients. Western-based Pharma assists the development of China's industry, the China Communist Party (CCP) by extension, and patients there. Guess which is under assault? Chief Editor Louis Garguilo tries to figure it all out.

2. CDMOs Pelted By Slings And Arrows 4/18/2024

   Chief Editor Louis Garguilo thought he was precipitating a frontal assault by canvassing the Outsourced Pharma Editorial Advisory Board with questions such as: When outsourcing development and manufacturing, what are the challenges, and where are your pain points? But before anyone claims “one-sided,” please read on.

3. You Want To Rein In China? Then Actually Do It 4/12/2024

   Chief Editor Louis Garguilo takes a hard look at proposed legislation H.R. 7085 - the BIOSECURE Act - and draws out some interesting angles and conclusions regarding the biopharma battle between the U.S. and China.

4. AI Is Unearthing New Drug Candidates, But It Still Needs Human Oversight 4/11/2024

   AI can accelerate timetables and minimize wasted resources by analyzing vast amounts of data, but human oversight is necessary to address the limitations and biases of AI systems.

5. From Ally To Adversary: BIO's Swift Rebuke Of WuXi 4/5/2024

   The CEO of the Biotechnology Innovation Organization (BIO) spearheading expulsion of WuXi Apptec relied on WuXi Biologics as CEO of the biotech he founded. More on this and some breaking news on the U.S. government's accusations regarding WuXi, from Chief Editor Louis Garguilo.

6. Gene Circuits And Biofabs: Building The Evolution 4/1/2024

   Can’t find a bio fabrication plant for your gene circuits? Chief Editor Louis Garguilo has located a candidate. It arrives in a for-contract, state-of-the-art capability being carved out by an emerging biopharma. Circuits and biofab described within.

7. Outsourcing Through An Industry-Government Battle 3/25/2024

   A PhRMA survey concludes 63% of member companies expect to shift at least some of their r&d investment away from small molecules as a result of the new legislation called the Inflation Reduction Act (IRA). But a lot of this movement has been ongoing for almost 20 years. So what's the real scene, as the industry and government are at loggerheads.

8. Impacts Of The Inflation Reduction Act (IRA) 3/18/2024

   Jesse Mendelsohn, a "pharmaceutical regulatory compliance and government pricing” guru, who manages a life sciences group of over 100 consultants, says currently the biggest disruptor to our industry in 2004 is the Inflation Reduction Act (IRA), the 2023 legislation passed by Congress and signed into law by President Biden. 

9. What Investors Teach Us About CDMO Selection 3/12/2024

   “My advice to a biotech when outsourcing to a CDMO is really understand what you want. I don’t mean this as a criticism, but selecting a CDMO is most often not within your circle of competence." Advice on overcoming that deficit from a successful biotech and CDMO investor. 

10. Drugging The Undruggable: Strategies And Future Directions 3/7/2024

    Progress with PROTACs and molecular glues hasn’t come without challenges, particularly in identifying the right chemistry starting point for drug development — a process known as hit discovery. This article looks at the role of CRISPR, screening assays, and more.